Toreforant

Toreforant

Names
IUPAC name 5-(4,6-dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-[3-(1-methylpiperidin-4-yl)propyl]pyrimidin-2-amine
Identifiers
CAS Number	952494-46-1
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL3301609
ChemSpider	31389942
DrugBank	DB12522
KEGG	D10735
PubChem CID	23650961
UNII	U6LA7G393X
InChI InChI=1S/C23H32N6/c1-15-12-16(2)21-20(13-15)27-22(28-21)19-14-25-23(26-17(19)3)24-9-5-6-18-7-10-29(4)11-8-18/h12-14,18H,5-11H2,1-4H3,(H,27,28)(H,24,25,26) Key: FCRFVPZAXGJLPW-UHFFFAOYSA-N
SMILES CC1=CC(=C2C(=C1)NC(=N2)C3=CN=C(N=C3C)NCCCC4CCN(CC4)C)C
Properties
Chemical formula	C23H32N6
Molar mass	392.551 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Toreforant (JNJ-38518168) is an orally-dosed selective antagonist of the histamine H₄ receptor that has been studied for various health conditions. It is the successor of a number of H₄-selective compounds developed by Johnson & Johnson. Phase IIa clinical trials completed as recently as November 2018 continue to suggest that toreforant is safe.

As of the end of 2020, there is no regulator-approved H₄ antagonist. In U.S. Phase II clinical trials, toreforant, by itself, did not show efficacy against eosinophilic asthma. The drug did show at least partial efficacy against rheumatoid arthritis in patients who were nonresponsive to methotrexate. As the H₄ receptor is widely implicated in the regulation of inflammatory states, the potential uses for an H₄ antagonist remain significant.

See also

• JNJ-7777120